Abstract

Peroxisome proliferator-activated receptors (PPARs) have been extensively studied for gene regulation in glucose and lipid metabolism. It has been recently implicated that PPARs regulate cellular proliferation and inflammatory responses; some agonists for PPARs ameliorate experimental autoimmune encephalomyelitis, a model of multiple sclerosis (MS) in humans. This article will outline current experimental evidence suggesting potential clinical benefits for patients with MS.

Keywords: PPAR, multiple sclerosis, experimental autoimmune encephalomyelitis, cytokine, inflammation